Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called ixazomib (also known as MLN9708) in
combination with dexamethasone and rituximab (the regimen is called IDR) as a possible
treatment for Waldenstrom's Macroglobulinemia (WM).